Spots Global Cancer Trial Database for advanced tumors
Every month we try and update this database with for advanced tumors cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of CS23546 in Subjects With Advanced Tumors | NCT06245122 | Advanced Tumors | CS23546 | 18 Years - | Chipscreen Biosciences, Ltd. | |
| A Study of CS23546 in Subjects With Advanced Tumors | NCT06245122 | Advanced Tumors | CS23546 | 18 Years - | Chipscreen Biosciences, Ltd. | |
| A SHR-1210 BE Study on Healthy Subjects | NCT05799183 | Advanced Tumors | SHR-1210 SHR-1210 | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma | NCT05390528 | Advanced Tumors Lymphoma Metastatic Tumo... | HLX301 | 18 Years - | Shanghai Henlius Biotech | |
| IKS014 in Advanced Solid Tumors That Express HER2 | NCT05872295 | Breast Cancer Gastric Cancer Gastroesophagea... | IKS014 | 18 Years - | Iksuda Therapeutics Ltd. | |
| Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | NCT00880308 | Advanced Solid ... Medulloblastoma Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| Phase I Study of CPI-300 in Patients With Advanced Tumors | NCT04808453 | Advanced Tumors | CPI-300 | 18 Years - | Coordination Pharmaceuticals, Inc. | |
| AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours | NCT00819221 | Solid Tumors | AZD2281 liposomal doxor... | 18 Years - 130 Years | AstraZeneca | |
| IKS014 in Advanced Solid Tumors That Express HER2 | NCT05872295 | Breast Cancer Gastric Cancer Gastroesophagea... | IKS014 | 18 Years - | Iksuda Therapeutics Ltd. | |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | NCT04521413 | Advanced Solid ... | CFI-402411 Pembrolizumab | 18 Years - | Treadwell Therapeutics, Inc | |
| Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | NCT00880308 | Advanced Solid ... Medulloblastoma Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| Study of BMS-986158 in Subjects With Select Advanced Cancers | NCT02419417 | Advanced Tumors | BMS-986158 Nivolumab | 12 Years - | Bristol-Myers Squibb | |
| The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor | NCT05061628 | Advanced Tumors | JS006 as Monoth... JS006 in combin... | 18 Years - 75 Years | Shanghai Junshi Bioscience Co., Ltd. | |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma | NCT05390528 | Advanced Tumors Lymphoma Metastatic Tumo... | HLX301 | 18 Years - | Shanghai Henlius Biotech | |
| A Study of PM1022 in Patients With Advanced Tumors | NCT05867771 | Advanced Tumors | PM1022 | 18 Years - 75 Years | Biotheus Inc. | |
| A Study of HRS2543 in Patients With Advanced Tumors | NCT05068856 | Advanced Tumors | HRS2543 | 18 Years - 70 Years | Shanghai Hengrui Pharmaceutical Co., Ltd. | |
| Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors | NCT05213767 | Advanced Tumors | TQB2916 injecti... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| An East Asian Study of LDE225 | NCT01208831 | Advanced Solid ... Medulloblastoma Basal Cell Carc... | LDE225 | 18 Years - | Novartis | |
| Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies | NCT04521413 | Advanced Solid ... | CFI-402411 Pembrolizumab | 18 Years - | Treadwell Therapeutics, Inc | |
| Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors | NCT05213767 | Advanced Tumors | TQB2916 injecti... | 18 Years - 75 Years | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | |
| Study of CPI-100 in Patients With Advanced Tumors | NCT03781362 | Advanced Tumors | CPI-100 Capecitabine | 18 Years - | Coordination Pharmaceuticals, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
